Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viral Upper Respiratory Tract Infection Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Elderberry for Immune Support

NCT05435144
View directory record Official record
Conditions
Upper Respiratory Tract Infection, COVID-19, Flu, Flu Like Illness, Cold
Interventions
Elderberry, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Alleviation of Common Cold Symptoms

NCT06106880
View directory record Official record
Conditions
Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions
Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet
Drug · Dietary Supplement · Other
Lead sponsor
Applied Biological Laboratories Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 29, 2026, 5:41 PM EDT
Completed No phase listed Observational Results available

The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years

NCT00405509
View directory record Official record
Conditions
Upper Respiratory Infection, Common Cold
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 13 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 29, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

NCT01249443
View directory record Official record
Conditions
HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 29, 2026, 5:41 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)

NCT03026205
View directory record Official record
Conditions
Viral Upper Respiratory Tract Infection
Interventions
ARMS-I
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

NCT05447078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 29, 2026, 5:41 PM EDT
Recruiting Not applicable Interventional

Reducing Overuse of Antibiotics With Decision Support

NCT06788093
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Pneumonia, Asthma, Bronchiolitis, Viral
Interventions
ED Clinical Decision Support (CDS-ED), Transitions Clinical Decision Support (CDS-Tr)
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 17 Years
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 29, 2026, 5:41 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT07149428
View directory record Official record
Conditions
Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis, COVID-19, Depression, Parosmia, Hyposomia, Normosomia, Anosmia
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 29, 2026, 5:41 PM EDT
Recruiting Phase 2 Interventional

Omalizumab Before Onset of Exacerbations

NCT05332067
View directory record Official record
Conditions
Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

NCT02957136
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions
Rapid respiratory pathogen nucleic acid amplification test
Device
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 101 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 29, 2026, 5:41 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2

NCT04815018
View directory record Official record
Conditions
SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection, Viral Respiratory Tract Infection
Interventions
Not listed
Lead sponsor
Pathnostics
Industry
Eligibility
60 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Delaware, Ohio • Granville, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

NCT06065176
View directory record Official record
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
Interventions
Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
Biological
Lead sponsor
Sarang K. Yoon, DO, MOH
Other
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 29, 2026, 5:41 PM EDT
Withdrawn Phase 3 Interventional

Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

NCT05026801
View directory record Official record
Conditions
Respiratory Tract Infection Viral
Interventions
Azithromycin plus hydroxychloroquine
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 29, 2026, 5:41 PM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Not applicable Interventional

A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases

NCT05035420
View directory record Official record
Conditions
COVID-19, Upper Respiratory Infection, Lower Respiratory Infection
Interventions
Fitbit, Douglas Bag, Periflux 6000 EPOS, BIOPAC, Flowmet, NIRS
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 78 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 29, 2026, 5:41 PM EDT
Completed No phase listed Observational

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

NCT00384462
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 6 Months
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
59
States / cities
Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway

NCT05467007
View directory record Official record
Conditions
Viral Infection, Acute Respiratory Infection, Upper Resp Tract Infection
Interventions
BioFire® Respiratory Panel 2.1-EZ
Diagnostic Test
Lead sponsor
Andrew Meltzer
Other
Eligibility
7 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 29, 2026, 5:41 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 29, 2026, 5:41 PM EDT
Completed No phase listed Observational

Impact of Respiratory Pathogens in Infants

NCT01789268
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
Respiratory Inductive Plethysmography
Device
Lead sponsor
University of Rochester
Other
Eligibility
0 Days to 3 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

NCT00189475
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Deborah Gentile
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 29, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

NCT02484417
View directory record Official record
Conditions
Upper Respiratory Tract Infection
Interventions
RSV A2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 29, 2026, 5:41 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 29, 2026, 5:41 PM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 29, 2026, 5:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform

NCT04663776
View directory record Official record
Conditions
Covid19, Influenza, Respiratory Tract Infections, Acute Respiratory Tract Infection, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 29, 2026, 5:41 PM EDT